| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/21/2005 | WO2005065318A2 Effervescent oral opiate dosage form |
| 07/21/2005 | WO2005065317A2 Effervescent oral fentanyl dosage form |
| 07/21/2005 | WO2005065308A2 Compositions and methods to treat recurrent medical conditions |
| 07/21/2005 | WO2005065266A2 Di-substituted pyrrolotriazine compounds |
| 07/21/2005 | WO2005065192A2 Photolabile compounds |
| 07/21/2005 | WO2005065185A2 Temperature-stable formulations, and methods of development thereof |
| 07/21/2005 | WO2005065183A2 Mitotic kinesin inhibitors |
| 07/21/2005 | WO2005065121A2 Methods and compositions for the production of monoclonal antibodies |
| 07/21/2005 | WO2005065079A2 Medical implants and fibrosis-inducing agents |
| 07/21/2005 | WO2005065069A2 Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease |
| 07/21/2005 | WO2005065050A2 Bicyclic compound |
| 07/21/2005 | WO2005056027A3 Solvent for biogenic active pharmaceutical ingredients |
| 07/21/2005 | WO2005049827A3 Ppmp as a ceramide catabolism inhibitor for cancer treatment |
| 07/21/2005 | WO2005049022A3 Use of dipeptidyl peptidase iv inhibitors |
| 07/21/2005 | WO2005049012A3 Tryptophan for use in promoting and maintaining abstinence |
| 07/21/2005 | WO2005047278A3 Substituted dihydroquinazolines ii |
| 07/21/2005 | WO2005047268A3 Substituted pyrimidine compositions and methods of use |
| 07/21/2005 | WO2005046722A3 Carbohydrate antigen-nanoparticle conjugates and uses thereof as antimetastatic agents in treating cancer |
| 07/21/2005 | WO2005044194A3 TREATMENT OR PREVENTION OF NEOPLASIA BY USE OF AN Hsp90 INHIBITOR |
| 07/21/2005 | WO2005043124A3 Chiral 1,8-diarylnaphthalenes, methods of making them, and their use as sensors |
| 07/21/2005 | WO2005042510A8 Tocopheryl polyethylene glycol succinate articles and process for preparing tpgs articles |
| 07/21/2005 | WO2005042497A3 Benzimidazoles useful as modulators of ion channels |
| 07/21/2005 | WO2005042478A3 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
| 07/21/2005 | WO2005042021A3 Pharmaceutical composition, containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha-reductase inhibitor |
| 07/21/2005 | WO2005039638A3 Therapeutic agent for heart failure comprising an angiotensin ii receptor antagonist and a matrix metalloproteinase inhibitor |
| 07/21/2005 | WO2005039494A3 Inhibitors of rnase p proteins as antibacterial compounds |
| 07/21/2005 | WO2005037824A3 Method for the production of amino crotonyl compounds |
| 07/21/2005 | WO2005037294A8 Compositions for controlling parasites comprising a combination of abamectin and ivermectin |
| 07/21/2005 | WO2005037212A3 Treatment of chemical dependency with substantially nonaddicting normorphine and norcodeine derivatives |
| 07/21/2005 | WO2005035490A3 PROCESS FOR SYNTHESIZING d-TOCOTRIENOLS |
| 07/21/2005 | WO2005032567A3 Method to treat the side effects associated with non steroidal anti-inflammatory drugs using microorganisms of the genus bifidobacterium |
| 07/21/2005 | WO2005027826A3 Methods and treating severe acute respiratory syndrome |
| 07/21/2005 | WO2005026193A3 Small molecules and a pharmacophore model for inhibition of botulinum toxin and methods of making and using thereof |
| 07/21/2005 | WO2005026137A3 Modulators of atp-binding cassette transporters |
| 07/21/2005 | WO2005020935A3 Method and composition of administering radioprotectants |
| 07/21/2005 | WO2005020911A3 Benzo[1, 3]dioxole compounds, pharmaceutical compositions thereof, and processes of making and using the same |
| 07/21/2005 | WO2005018604A3 Novel inhalation powder comprising the cgrp antagonist 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazine |
| 07/21/2005 | WO2005018603A3 Spray-dried amorphous bibn 4096 method for production and use thereof as inhalant |
| 07/21/2005 | WO2005018561A3 Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use |
| 07/21/2005 | WO2005013914A3 Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain |
| 07/21/2005 | WO2005013905A3 SENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING ssRNA VIRAL INFECTION |
| 07/21/2005 | WO2005011607A3 Treatment of cancers expressing p95 erbb2 |
| 07/21/2005 | WO2004099279A8 Heat activated tertiary amine urethane catalysts |
| 07/21/2005 | WO2004091506A3 Taxane-based compositions and methods of use |
| 07/21/2005 | WO2004087095A3 Osmotic controlled release device containing zafirlukast and an h1-antagonist |
| 07/21/2005 | WO2004087051A3 Ophthalmic compositions for treating ocular hypertension |
| 07/21/2005 | WO2004087045A3 Devices, methods, and compositions to prevent restenosis |
| 07/21/2005 | WO2004043920A8 Polymorphs of bicifadine hydrochloride |
| 07/21/2005 | WO2004024134A8 Pharmaceutical formulations of modafinil |
| 07/21/2005 | WO2004024064A8 Compositions and methods for the diagnosis and treatment of tumor |
| 07/21/2005 | WO2004018648A3 Methods for treating patients and identifying therapeutics |
| 07/21/2005 | WO2003105811A8 Controlled release compositions and methods for using same |
| 07/21/2005 | WO2003090673A3 Compositions and methods for promoting weight loss, thermogenesis, appetite suppression, lean muscle mass, increasing metabolism and boosting energy levels, and use as a dietary supplement in mammals |
| 07/21/2005 | US20050159695 Comprises antimicrobial substances, pain relievers, protease inhibitors, kallikrein, and tissue-plasminogen activator |
| 07/21/2005 | US20050159611 Process for producing shogaols and intermediates for the synthesis thereof |
| 07/21/2005 | US20050159600 Crystalline R-guanidines, arginine or (L)-arginine (2S)-2-ethoxy-3-{4-[2-(10H-phenoxazin-10-yl)ethoxy]phenyl}propanoate |
| 07/21/2005 | US20050159598 Activators of human peroxisome proliferator activated receptors such as {2-[2-fluoro-4-(trifluoromethyl)phenyl]-4-methyl-1,3-thiazol-5-yl}methanol |
| 07/21/2005 | US20050159585 Forming acyl azide function on acid group of amino acid derivative, then transforming to isocyanate |
| 07/21/2005 | US20050159584 O-succinimidyl-2-[(9H-fluoren-9-ylmethoxy)carbonylamino]-ethylcarbamate's used as monomers active in the synthesis of di- and tri-substituted ureas and urea oligomers |
| 07/21/2005 | US20050159493 Alzheimer's disease; small molecule amine salts |
| 07/21/2005 | US20050159492 Enhancing bioavailability of oral immediate release tablets for low solubility medicants; respiratory inflammatory disorders |
| 07/21/2005 | US20050159491 Cerebrovascular and cardiovascular diseases; hot water extracting danshen plant and chromatographic separation on polyamide column; high yield, low cost, quality |
| 07/21/2005 | US20050159490 Increasing mean cardiac output without materially increasing heart rate utilizing thyroid hormone analog |
| 07/21/2005 | US20050159489 Treatment of diabetes with copper binding compounds |
| 07/21/2005 | US20050159488 D-serine transport antagonist for treating psychosis |
| 07/21/2005 | US20050159487 Cyclic amino acids and derivatives thereof useful as pharmaceutical agents |
| 07/21/2005 | US20050159486 Offsetting effects of bypass surgery and chronic or acute illnesses with conjugated octadecadienoic acids; reducing metabolic disfunction |
| 07/21/2005 | US20050159485 Prostaglandin and retinoid; low dosage; reduced toxicity and cost |
| 07/21/2005 | US20050159483 Method of using punicic acid to enhance immune response and prevent metabolic disorders |
| 07/21/2005 | US20050159481 4,6-di-t-butyl-5-hydroxy-2,2-di-n-pentyl-2,3-dihydrobenzofuran; side effect reduction: lowers high-density lipoprotein cholesterol (HDL-C), prolongs electrocardiographic QT intervals; myocardial infarction, hypotensive, antidiabetic, anticoagulant, arteriosclerosis obliterans, intermittent claudication |
| 07/21/2005 | US20050159480 Preparation of statins by reacting (trisubstituted phosphoranylidenecarbonyl)acetates with benzaldehydes, reduction with diamino-group 8 metal coordinates, condensation with 1-hydroxy-1-alkoxyethylenes, hydrolysis, and optionally converting the carboxy acid product into a salt or a lactone |
| 07/21/2005 | US20050159478 Compositions containing d-tocopherol compound polybasic acid partial esters |
| 07/21/2005 | US20050159477 Prepared by suspending pseudomonic acid in water and gradually adding calcium hydroxide to pH of 7.8-8.5, filtering, and lyophilizing frozen solution of calcium pseudomonate in water; stable topical pharmaceutical preparations |
| 07/21/2005 | US20050159476 Pharmaceutical composition for preventing or treating respiratory disease |
| 07/21/2005 | US20050159475 Making intermediates to alpha-ethyl-2-oxo-1-pyrrolidine acetamide, also referred to as levetiracetam an antihypoxic agent and antiischemic agent; by reduction via catalytic hydrogenation of an alkenyl intermediate |
| 07/21/2005 | US20050159474 Chemical compounds |
| 07/21/2005 | US20050159473 3-Substituted oxindole beta3 agonists |
| 07/21/2005 | US20050159472 Chemical compounds |
| 07/21/2005 | US20050159471 Compositions of a benzenesulfonamide or methylsulfonylbenzene cyclooxygenase-2 selective inhibitor and a cholinergic agent for the treatment of reduced blood flow or trauma to the central nervous system |
| 07/21/2005 | US20050159470 Histone deacetylase inhibitors |
| 07/21/2005 | US20050159469 HIV protease inhibiting compounds |
| 07/21/2005 | US20050159468 Drugs for antiproliferation agent for pyrrolidine compounds |
| 07/21/2005 | US20050159467 5-Aryltetrazole compounds and uses thereof |
| 07/21/2005 | US20050159466 Production method of isoxazolidinedione compound |
| 07/21/2005 | US20050159463 5-methoxy-3-(2-(2-furamido) ethyl)indole; related to melatonin, but pharmacologicaly and pharmacokineticy different; longer duration, selective localization and greater efficacy |
| 07/21/2005 | US20050159462 Elevates extracellular adenosine concentration for antiinflammatory and immunosuppressive effects; reaction of imidazole-4-carboxamide with a hydroxyalkylbenzoxazole or benzothiazole compound; 1-[4-hydroxy-1-(2-phenyl-4-benzoxazolyl)-3-pentyl]-imidazole-4-carboxamide |
| 07/21/2005 | US20050159461 Treating cancer with a synergistic mixtures; anticarcinogenic agents; epothilone has secondary amide instead of an ester |
| 07/21/2005 | US20050159460 2-[(1R,3S,4S)-1-benzyl-4-t-butoxycarbonylamino-3-hydroxy-5-phenylpentyl]-5-butyl-thiazole; for inhibiting beta-secretase-mediated cleavage of amyloid precursor protein, particularly to inhibit production of A beta peptide; treatment of diseases associated with a pathological form of A beta peptide |
| 07/21/2005 | US20050159459 inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful to reduce forming beta peptides |
| 07/21/2005 | US20050159457 Aminopyridinyl-, aminoguanidinyl- and alkoxyguanidinyl-substituted phenyl acetamides as protease inhibitors |
| 07/21/2005 | US20050159456 Method of treating of demyelinating diseases or conditions |
| 07/21/2005 | US20050159455 1,4-dihydropyridine and pyridine compounds as calcium channel blockers |
| 07/21/2005 | US20050159453 Administering to a patient an effective amount of a peripheral mu opioid antagonist compound, including piperidine-N-alkylcarboxylates, quaternary morphinans, opium alkaloid derivatives; treatment of postsurgical and postpartum gastrointestinal disorders |
| 07/21/2005 | US20050159452 Nociceptin analogs |
| 07/21/2005 | US20050159451 NMDA (N-methyl-D-aspartate) receptors; eg 6-(4-benzylpiperidin-1-carbonyl)-1,5-dihydro-oxazolo[4,5-f]indole-2-one |
| 07/21/2005 | US20050159450 Derivative of n-[phenyl(piperidin-2-yl)methyl]benzamide, the preparation method thereof and application of same in therapeutics |
| 07/21/2005 | US20050159447 Quinoline derivative anticarcinogenic compounds; based on herbicides |
| 07/21/2005 | US20050159446 of preparing 4-substituted quinoline compounds as intermediates in the manufacture of receptor tyrosine kinase inhibitors and intermediate compounds used in the methods thereof, wherein the 4-substituted quinoline compound has the following general formula (I): |
| 07/21/2005 | US20050159445 Selective iGluR5 receptor antagonists |
| 07/21/2005 | US20050159444 Bicyclic unsaturated tertiary amine compounds |